Vis enkel innførsel

dc.contributor.authorMelby, Katrine
dc.contributor.authorNygård, Mona
dc.contributor.authorBrobakken, Mathias Forsberg
dc.contributor.authorGråwe, Rolf W.
dc.contributor.authorGuzey, Ismail Cuneyt
dc.contributor.authorReitan, Solveig Merete Klæbo
dc.contributor.authorVedul-Kjelsås, Einar
dc.contributor.authorHeggelund, Jørn
dc.contributor.authorLara Cabrera, Mariela Loreto
dc.date.accessioned2021-04-30T09:36:51Z
dc.date.available2021-04-30T09:36:51Z
dc.date.created2021-04-28T14:29:47Z
dc.date.issued2021
dc.identifier.citationInternational Journal of Environmental Research and Public Health (IJERPH). 2021, 18>1185 (3), 1-8.en_US
dc.identifier.issn1661-7827
dc.identifier.urihttps://hdl.handle.net/11250/2740553
dc.description.abstractPatient Activation Measure-13 (PAM-13) is a valid and widely used questionnaire that assess an individual’s knowledge, confidence, and skills for self-management of their chronic illness. Although there is some evidence regarding its reliability, the test–retest reliability has not been investigated among patients with substance use disorders (SUDs) or schizophrenia spectrum disorders. We investigated the internal consistency and test–retest reliability of PAM-13 in these populations. Test–retest reliability was analysed using data from 29 patients with SUDs and 28 with schizophrenia spectrum disorders. Cronbach’s α and Intraclass Correlation Coefficient (ICC) scores were used to examine internal consistency and test–retest reliability, respectively. Of the 60 collected test–retest questionnaires, 57 were included in the analyses. No mean differences between time one (T1) and time two (T2) were observed in either patient group, except for item 12 in schizophrenia spectrum disorders patients (p < 0.05). Internal consistency for T1 and T2 was 0.75 and 0.84 in SUDs patients and 0.87 and 0.81 in schizophrenia spectrum disorders patients, respectively. The ICC was r = 0.86 in patients with SUDs and r = 0.93 in patients with schizophrenia spectrum disorders. To conclude, PAM-13 showed good internal consistency and test–retest reliability in SUDs and schizophrenia spectrum disorders patients.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleTest-retest reliability of the patient activation measure-13 in adults with substance use disorders and schizophrenia spectrum disordersen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-8en_US
dc.source.volume18>1185en_US
dc.source.journalInternational Journal of Environmental Research and Public Health (IJERPH)en_US
dc.source.issue3en_US
dc.identifier.doi10.3390/ijerph18031185
dc.identifier.cristin1906999
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal